Pralmorelin

Also known as: GHRP-2, KP-102 D

Growth HormonePHASE 2

Clinical Status

Approved in Japan for GH deficiency diagnosis. Research compound elsewhere.

Mechanism of Action

A synthetic hexapeptide ghrelin receptor agonist approved in Japan for diagnosing growth hormone deficiency. Produces robust GH release via GHSR-1a activation in the pituitary, with predictable dose-response kinetics.

Dosing Defaults

Dose

100 mcg (diagnostic)

Frequency

Single diagnostic dose or 2-3x daily (research)

Administration

Intravenous (diagnostic) or subcutaneous

Timing

Morning fasted (diagnostic)

Food

fasted

Duration

Single use (diagnostic) or 8-12 weeks (research)

Dose range: 1 mcg/kg IV (diagnostic) or 100-300 mcg SC

Overnight fast required for accurate diagnostic GH response.

Side Effects

•Increased appetite
•Flushing
•Dizziness
•Headache
•Elevated cortisol
•Elevated prolactin

Contraindications & Warnings

⚠Active malignancy

•Not medical advice
•Approved for diagnostic use in Japan only

Compare

Compare Pralmorelin with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Pralmorelin dose.

Open Calculator

Related Growth Hormone Peptides

Ipamorelin

PHASE 2

Growth Hormone

Selective GH secretagogue. Considered one of the safest GHRPs.

CJC-1295

PHASE 2

Growth Hormone

Synthetic GHRH analog that stimulates GH release from the pituitary.

CJC-1295 DAC

PHASE 2

Growth Hormone

Long-acting version of CJC-1295 with extended half-life via albumin binding.

Tesamorelin

FDA APPROVED

Growth Hormone

FDA-approved GHRH analog for visceral fat reduction in HIV lipodystrophy.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.